Thelansis

Hyperoxaluria Market Outlook Thelansis’s “Hyperoxaluria Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hyperoxaluria treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do inter...

Hyperoxaluria Market Outlook Thelansis’s “Hyperoxaluria Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hyperoxaluria     treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Hyperoxaluria Overview Hyperoxaluria is caused by an excessive dietary intake (dietary oxaluria), gastrointestinal disorders or surgery that results in excessive oxalate absorption (enteric oxaluria), or rarely an enzyme deficiency that results in excessive oxalate production (PHO).   Geography coverage: G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China) Insights driven by robust research, including: In-depth i...

 Hyperoxaluria is caused by an excessive dietary intake (dietary oxaluria), gastrointestinal disorders or surgery that results in excessive oxalate absorption (enteric oxaluria), or rarely an enzyme deficiency that results in excessive oxalate production (PHO). ·        A survey suggested that in the United States, approximately 1 out of 11 people suffered from renal stones.   Thelansis’s “Hyperoxaluria Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hyperoxaluria treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).   KOLs insights of Hyperoxaluria across 8 MM market from the centre of Exce...

 Hyperoxaluria is caused by an excessive dietary intake (dietary oxaluria), gastrointestinal disorders or surgery that results in excessive oxalate absorption (enteric oxaluria), or rarely an enzyme deficiency that results in excessive oxalate production (PHO). ·        A survey suggested that in the United States, approximately 1 out of 11 people suffered from renal stones. Thelansis’s “Hyperoxaluria Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hyperoxaluria treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Hyperoxaluria across 8 MM market from the centre of Excellence/ Public/ ...

Hyperoxaluria results from excessive dietary intake (dietary oxaluria), gastrointestinal disorders or surgery that lead to excess oxalate absorption (enteric oxaluria), or rarely an enzyme deficiency that results in excessive production of oxalate (PHO).   Etiology- Hyperoxalurias can be broadly divided into primary and secondary based on their etiology:   Primary hyperoxaluria is caused by an inherent defect or absence of enzyme activity, ultimately leading to increased levels of oxalate in the body. ·        Primary hyperoxaluria type 1: Glyoxalate is produced as an intermediate molecule in the metabolism of hydroxyproline, glycolate, and glycine and is generally detoxified in the peroxisome of the hepatocytes by the enzyme alanine:glyoxylate-aminotransferase (AGT), which converts glyoxalate to glycine. ·        Primary hyperoxaluria type 2: On chromosome 10, the gene GRHPR codes for the enzyme glyoxalate/ hydroxypy...